Current label answer
Both branded liraglutide labels list the abdomen, thigh, or upper arm
The current manufacturer Saxenda and Victoza prescribing information lists subcutaneous injection in the abdomen, thigh, or upper arm. Each label directs rotation within the same region and says that changing the labeled site does not itself require a dosage adjustment. That is product-label guidance, not proof that every pen, compounded preparation, or other injectable medicine uses the same sites or handling instructions.
- Saxenda and Victoza are once-daily branded liraglutide injections, but they have different FDA-labeled uses and product-specific instructions.
- The three listed body areas are labeled options; the labels do not name one area as more effective for weight loss or glucose control.
- Use the exact package, pharmacy label, and instructions supplied with the product rather than a seller chart, social post, or another brand’s diagram.
Brand and indication identity
Saxenda and Victoza share liraglutide but are not interchangeable pens
Saxenda and Victoza are FDA-approved brand products containing liraglutide, but current Saxenda labeling addresses long-term weight reduction in eligible patients while Victoza labeling addresses type 2 diabetes glycemic control and selected adult cardiovascular-risk reduction. Their labeled uses, pen instructions, strength systems, coverage contexts, and monitoring goals differ. Peptide12 does not list Saxenda or Victoza in its current catalog; this page is decision support for patients comparing injection logistics and clinician-reviewed alternatives.
- Confirm the brand name, active ingredient, intended condition, pen, prescriber, dispensing pharmacy, storage history, and supplied instructions before discussing a site.
- Do not combine the brands, transfer pen settings, copy a conversion, or treat one as a generic version of the other.
- Peptide12 currently lists other semaglutide and tirzepatide injection paths; those are different products that require their own eligibility, label or compounded-prescription, safety, and access review.
Rotation and repeated spots
Rotation is about avoiding repeated use of the same tissue—not chasing a stronger effect
Both current labels direct patients to rotate injection sites within the same region to reduce the risk of cutaneous amyloidosis, a persistent localized protein deposit reported with repeated injections into the same area. The labels also note that localized cutaneous amyloidosis can be associated with delayed absorption when medicine is injected into the affected site. This supports a clinician-reviewed rotation plan and examination of a persistent lump; it does not support changing the dose, repeating an uncertain injection, or using a lump as proof that the medication failed.
- Record the general area used and avoid repeatedly targeting the exact same spot when following the product-specific plan.
- Ask for clinical review of a persistent firm area, lump, skin thickening, indentation, recurrent local reaction, or uncertainty about available sites.
- Do not inject into a concerning area to test absorption, massage or puncture a lump, or compensate with extra medicine.
Reach and exact instructions
Upper-arm guidance can depend on the exact product instructions
The current Victoza instructions for use specify that the upper arm should be used only when a caregiver administers the injection. That product-specific detail should not be silently transferred to Saxenda, another pen, or a patient-specific prescription. Reach, vision, dexterity, tremor, caregiver availability, scars, bruising, irritated skin, and prior reactions can all change whether a labeled area is practical. A prescriber, pharmacist, or manufacturer support team should review the exact presentation when assistance or technique is unclear.
- Do not twist, reach, or improvise around limited mobility simply because the upper arm appears on a general site list.
- Bring the exact pen and instructions to a technique review; do not substitute a video made for another brand or presentation.
- A partial, leaking, painful, or uncertain injection needs product-specific advice—not an automatic repeat dose.
Insulin and other injections
A shared body region does not mean medicines can be mixed or placed together
Current Victoza labeling says that when Victoza is used with insulin, the medicines should be administered as separate injections and never mixed. It says they may be injected in the same body region but should not be adjacent. That statement is specific to labeled Victoza and insulin use and does not create a universal plan for another injectable medicine or a compounded preparation. Diabetes medicines also require patient-specific glucose and hypoglycemia review.
- Tell the care team about insulin, sulfonylureas, other GLP-1 or incretin medicines, and every injectable prescription or supplement.
- Do not put liraglutide and insulin in one syringe, place injections next to each other, or invent a combined rotation plan.
- Ask the diabetes-care clinician or pharmacist to document how separate products, sites, glucose monitoring, meals, and low-blood-sugar risk fit together.
Local symptoms and escalation
A local mark needs a symptom trend and product check—not a one-size-fits-all timeline
Redness, itching, tenderness, warmth, swelling, bruising, firmness, a lump, or another local change can have more than one cause, including irritation, repeated tissue exposure, allergy, infection, bleeding risk, skin disease, or product and handling problems. The current labels do not establish one universal size or duration for every local symptom. Record the exact product, site, onset, border and size trend, pain, warmth, drainage, fever, hives, symptoms away from the site, and anything new that touched the skin.
- Contact the prescriber about a persistent, recurrent, spreading, worsening, unusually painful, or treatment-limiting reaction before another treatment decision.
- Seek prompt in-person care for rapidly spreading redness or swelling, severe or escalating pain, pus, red streaks, fever, blistering, darkening, numbness, skin breakdown, or feeling acutely unwell.
- Trouble breathing, face or throat swelling, fainting, or widespread hives can require emergency care rather than portal messaging.